NMPA Unveils 30‑Working‑Day Pathway to Accelerate Innovative Drug Trials
DrugPolicy / Regulatory

NMPA Unveils 30‑Working‑Day Pathway to Accelerate Innovative Drug Trials

Genrix Bio Secures NMPA Approval for GR1803 Bispecific Antibody in Systemic Lupus Erythematosus
CompanyDrug

Genrix Bio Secures NMPA Approval for GR1803 Bispecific Antibody in Systemic Lupus Erythematosus

GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58 B
CompanyDeals

GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58 B

Remedium Bio Teams Up With Eli Lilly to Push Gene‑Therapy Frontiers for Diabetes and Obesity
CompanyDeals

Remedium Bio Teams Up With Eli Lilly to Push Gene‑Therapy Frontiers for Diabetes and Obesity

YolTech Raises 300 Million Yuan Series B, Pushing In‑Vivo Gene‑Editing to the Forefront
CompanyDeals

YolTech Raises 300 Million Yuan Series B, Pushing In‑Vivo Gene‑Editing to the Forefront

Novartis Secures Tabrecta Approval in China for METex14 NSCLC
CompanyDrug

Novartis Secures Tabrecta Approval in China for METex14 NSCLC

China to Add HPV Vaccine to National Immunization Program, Pledges Free Shots for Eligible Girls
CompanyDrug

China to Add HPV Vaccine to National Immunization Program, Pledges Free Shots for Eligible Girls

China’s Drug Evaluation Authority Issues Draft Rules for Class I ATMP Meetings
Policy / Regulatory

China’s Drug Evaluation Authority Issues Draft Rules for Class I ATMP Meetings

China Unveils “Healthcare Foundation Strengthening Plan” to Bring Clinics Within 15‑Minute Reach
Policy / Regulatory

China Unveils “Healthcare Foundation Strengthening Plan” to Bring Clinics Within 15‑Minute Reach

TransThera Sciences Secures China Phase II Trial Approval for Tinengotinib‑Fulvestrant Combination
CompanyDrug

TransThera Sciences Secures China Phase II Trial Approval for Tinengotinib‑Fulvestrant Combination

Innovent Biologics & Cowell Health Forge Strategic Alliance to Boost Drug Access
CompanyDeals

Innovent Biologics & Cowell Health Forge Strategic Alliance to Boost Drug Access

Taiji Group Secures NMPA Approval to Begin Clinical Trials of Semaglutide Biosimilar
CompanyDrug

Taiji Group Secures NMPA Approval to Begin Clinical Trials of Semaglutide Biosimilar